Erythropoietin does not increase the frequency of thromboembolic events or hepatocellular carcinoma in hepatitis C patients treated with combination antiviral therapy.
Gallegos-Orozco
Juan F
JF
Werner
Kristina T
KT
Rosati
Marianne
M
Byrne
Thomas J
TJ
Balan
Vijayan
V
Vargas
Hugo E
HE
Rakela
Jorge
J
D000328:Adult; D000740:Anemia / Q000139:chemically induced / Q000517:prevention & control; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D013923:Thromboembolism / Q000453:epidemiology*
D000998:Antiviral Agents; D004921:Erythropoietin